Clofarabine, CAS# 123318-82-1, is also known as the brand name Clolar. As an injectable medication used to treat relapsed or refractory acute lymphoblastic leukemia, clofarabine is typically administered after at least two prior regimens. Clofarabine is indicated for the pediatric population, ages 1 to 21 years of age. A common treatment regimen is 52 mg/m2 intravenously, as an infusion over 2 hours daily for a total of 5 consecutive days. If the patient develops hypotension within the first 5 days of treatment it is suggested that treatment is discontinued. Additionally, patients should have minimal or no exposure to drugs which have renal toxicity during the five days of treatment with clofarabine, as this may significantly increases their risk of renal toxicity. With any cancer treatment there are risks of adverse effects, but the common side effects of clofarabine are rather mild, and can include chills, fatigue and diarrhea.
One particularly successful study of clofarabine involved 61 pediatric patients with acute lymphoblastic leukemia, also known as the ALL study. This single-arm study focused on this group of patients who had relapsed or experienced their disease becoming refractory after two or more previous therapies. The pediatric patients in the study were administered a dose of 52 mg/m2 for five consecutive days, over a two hour period each of these days. The treatment regimen was repeated every 2 to 6 weeks for a total of up to 12 treatments. The overall remission rate proved to be encouraging, with roughly 20 patients experiencing success after the clofarabine treatments. The information gleaned from this specific study certainly provides hope for patients with this often fatal form of childhood leukemia.
LGM Pharma provides clofarabine for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.